Relationship between cytokine release and stress hyperglycemia in patients hospitalized with COVID-19 infection

Andrea Da Porto1*, Carlo Tascini2, Gianluca Colussi1, Maddalena Peghin3, Elena Graziano2, Chiara De Carlo2, Luca Bufone1, Martina Antonello1, Emanuela Sozio3, Martina Fabris1, Francesco Curcio3, Carlo Pucillo4, Cristina Catena1 and Leonardo A. Sechi3

1Division of Internal Medicine, Department of Medicine, University of Udine, Udine, Italy, 2Division of Infectious Diseases, Department of Medicine, University of Udine, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, 3Division of Laboratory Medicine, University of Udine, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, 4Laboratory of Immunology, Department of Medicine, University of Udine, Udine, Italy

Introduction: Stress hyperglycemia is a frequent finding in patients with COVID-19 infection and could affect the outcome of disease. Cytokines released in response to infection could have adverse effects on insulin sensitivity and pancreatic beta-cell function. The aim of the study was to examine the relationships of stress hyperglycemia with cytokines and clinical outcomes in hospitalized patients with COVID-19.

Methods: In a cross-sectional analysis of 150 patients hospitalized for COVID-19 infection who were included in the GIRA-COVID database, we identified patients with stress hyperglycemia by calculation of the Stress Hyperglycemia Ratio (SHR) and use of a cut-off of 1.14. Plasma levels of cytokines principally involved in COVID-19 infection-related cytokine storm were measured. Outcome variables were used of mechanical ventilation and death within 60 days from hospital admission.

Results: Patients with SHR > 1.14 had significantly higher plasma insulin, HOMA-index, and levels of interleukin-10 (IL-10), interleukin-10/tumor necrosis factor-α ratio (IL-10/TNF-α), and CXC motif chemokine ligand 10 (CXCL10) than patients with SHR ≤ 1.14. IL-10, IL-10/TNF-α ratio, CXCL10, and IFN-γ were significantly and directly related with SHR in univariate analysis and multivariate logistic regression models showed that IL-10, IL-10/TNF-α ratio, and CXCL10 were independently associated with SHR > 1.14. In a multivariate logistic model, stress hyperglycemia predicted use of mechanical ventilation (OR 2.453; CI 1.078–6.012) and death (OR 2.281; CI 1.049–7.369) independently of diabetes and other major confounders.

Conclusions: In patients hospitalized for COVID-19 infection, stress hyperglycemia is associated with worse clinical outcomes and is
could possibly damage pancreatic
tissue. Studies have shown that stress
deficits and intensive care units
commonly used in critical care medicine.

Recent evidence demonstrates elevated prevalence of stress
hyperglycemia and new onset diabetes in patients hospitalized with SARS-CoV-2 infection. This prevalence appears
disproportionately high when it is compared with what seen with other acute illnesses. Previous studies suggest
that hyperglycemia on admission is a strong predictor of poor outcome among patients hospitalized with SARS-CoV-2
infection. On the other hand, in patients with type 2 diabetes, SARS-CoV-2 infection has been associated with rapid
deterioration of glycemic control possibly leading to ketoacidosis or hyperosmolar hyperglycemia.

To date, no clear answer exists to explain why SARS-CoV-2 infection causes stress hyperglycemia with such high frequency.
Although almost any acute inflammatory state impairs insulin sensitivity and glucose disposal through activation of counter-
regulatory hormones and proinflammatory cytokines, this effect appears to be more pronounced in patients with SARS-CoV-2
infection. This might hypothetically be related to the unrestrainable cytokine storm that occurs in patients with severe SARS-CoV-2
infection. Many cytokines and chemokines that are released during the acute phase response to SARS-CoV-2 infection could possibly damage pancreatic beta-cells and impair insulin sensitivity, but their relationship with stress hyperglycemia is still unknown. The aim of this study was to examine the relationships between stress hyperglycemia and circulating cytokines and their relevance for clinical outcomes in patients hospitalized with SARS-CoV-2 infection.

**Methods**

This is a cross-sectional analysis of the GIRA-COVID database that was a prospective, observational, study conducted in 2021 at the University Hospital-University of Udine, a

**Introduction**

The association between acute hyperglycemia and worse outcomes in acute care settings is well known. Studies conducted in non-diabetic subjects admitted to medical wards and intensive care units have shown that stress hyperglycemia is an independent predictor of prolonged hospital stay and in-hospital mortality. It is known also that critically ill patients frequently develop hyperglycemia upon hospital admission regardless of pre-existing diabetes. Recent evidence demonstrates elevated prevalence of stress hyperglycemia and new onset diabetes in patients hospitalized with SARS-CoV-2 infection. This prevalence appears disproportionately high when it is compared with what seen with other acute illnesses. Previous studies suggest that hyperglycemia on admission is a strong predictor of poor outcome among patients hospitalized with SARS-CoV-2 infection. On the other hand, in patients with type 2 diabetes, SARS-CoV-2 infection has been associated with rapid worsening of glycemic control possibly leading to ketoacidosis or hyperosmolar hyperglycemia.

To date, no clear answer exists to explain why SARS-CoV-2 infection causes stress hyperglycemia with such high frequency. Although almost any acute inflammatory state impairs insulin sensitivity and glucose disposal through activation of counter-regulatory hormones and proinflammatory cytokines, this effect appears to be more pronounced in patients with SARS-CoV-2 infection. This might hypothetically be related to the unrestrainable cytokine storm that occurs in patients with severe SARS-CoV-2 infection. Many cytokines and chemokines that are released during the acute phase response to SARS-CoV-2 infection could possibly damage pancreatic beta-cells and impair insulin sensitivity, but their relationship with stress hyperglycemia is still unknown. The aim of this study was to examine the relationships between stress hyperglycemia and circulating cytokines and their relevance for clinical outcomes in patients hospitalized with SARS-CoV-2 infection.

**Methods**

This is a cross-sectional analysis of the GIRA-COVID database that was a prospective, observational, study conducted in 2021 at the University Hospital-University of Udine, a

**Laboratory data**

Identification of SARS-CoV-2 infection was based on the detection of unique sequences of virus RNA by nucleic acid amplification tests (NAAT) such as real-time PCR (RT-PCR) on a nasopharyngeal swab. The SARS-CoV-2 E gene was used for screening and RdRp and N genes for confirmation. The viral RNA was extracted by using automated RNA extraction with the ELITE InGenius® SP200 System (ELITechGroup 92800 Puteaux • France) and RT-qPCR was performed using a LightMix® Modular SARS and Wuhan CoV E-gene kit on a

**KEYWORDS**
cytokines, COVID-19, new onset diabetes, Stress Hyperglycemia Ratio, outcomes, humoral immune response, immunoparalysis
LightCycler® 480 II instrument (Roche). The specimens were considered positive if the cycle threshold value for at least one of the three genes was ≤36. The RT-PCR was conducted as recommended by the WHO for COVID-19 clinical management and outbreak control purposes.

At hospital admission and before starting intensive insulin treatment, venous blood samples were obtained for measurement of blood glucose, glycated hemoglobin (HbA1c), plasma insulin and lipids, C-reactive protein (CRP), and pro-adrenomedullin. A magnetic bead-based multiplex assay (Bio-Plex Pro Custom Human Cytokines and Chemokine Panel, procarta-Plex, Bio-Rad Laboratories, San Jose, California, 95134 USA) quantified several cytokines and chemokines: interleukin-1β (IL-1β, normal range <0.16 pg/ml), interleukin-6 (IL-6, normal range ≤ 7 pg/ml), interleukin-8 (IL-8, normal range 7–16 pg/ml), tumor necrosis factor-α (TNF-α, normal range 8–12 pg/ml), C-X-C motif chemokine ligand 10 (CXCL10, normal range 37–222 pg/ml), interferon-γ (IFN-γ, normal range < 0.99 pg/ml), interleukin-10 (IL-10, normal range 1.8–3.8 pg/ml), interleukin-2α (IL-2α, normal range 440–1,435 pg/ml). All the other laboratory biomarkers were evaluated using routine certified diagnostic methods.

**Definition of stress hyperglycemia and insulin resistance**

The Stress Hyperglycemia Ratio (SHR) was used for assessment of stress hyperglycemia. SHR is the ratio between blood glucose on admission and the previous average glucose level that is estimated from glycated hemoglobin (HbA1c) value using the equation 1.59 × HbA1c – 2.59, as proposed by Roberts et al. (13). Stress hyperglycemia was considered to be present when SHR was >1.14 according to the previous literature (13). The Homeostatic Model Assessment index (HOMA-IR) was used as an estimate of insulin sensitivity (fasting serum insulin (µU/ml) × fasting plasma glucose (mmol/l-1)/22.5). The triglyceride/glucose (TyG) index was also defined as log [fasting triglycerides (mg/dl) × fasting glucose (mg/dl)/2].

**Statistical analysis**

Values of normally distributed variables are expressed as mean ± standard deviation and skewed variables as median and interquartile range. Normality of distribution of the study variables was assessed by the Kolmogorov–Smirnov test and skewed variables were analyzed after logarithmic conversion. Pearson’s chi-squared test was used to compare frequency distributions. Spearman’s correlation coefficient was used to express the correlation between cytokines and stress hyperglycemia. Logistic regression analysis was performed to identify which variables were independent predictors of a SHR of more than 1.14. In this analysis, variables were sequentially entered in a stepwise model according to the strength of statistical significance obtained in the univariate analysis. The association between stress hyperglycemia and clinical outcomes was evaluated in a multivariate logistic regression model where stress hyperglycemia was included either as values of SHR >1.14 or SHR tertiles. A two-tailed probability value of less than 5% was considered to indicate statistical significance. Data analyses were performed using XLSTAT 2020 (Addinsoft, New York, NY, USA).

**Results**

Over the study period, 200 patients were admitted to our clinic with a confirmed diagnosis of COVID-19 infection. Overall, 150 patients had complete data for assessment of SHR and cytokines and chemokines measurements. The clinical characteristics of the study patients are shown in Table 1 where patients are grouped according to presence or absence of stress hyperglycemia. Age of patients included in the study was 69.9 ± 12.4 years, 35 % were male, and body mass index (BMI) and waist circumference were 28.2 ± 5.4 kg/m² and 103 ± 13 cm, respectively. Hypertension was present in 59% of patients, 37% had type 2 diabetes mellitus, and 31% had history of cardiovascular disease. Blood glucose on admission was 6.5 mmol/l (IQR 5.3–8.4) and median HbA1c 6.3% (IQR 5.8–6.8). Most patients (62%) had severe COVID-19 disease as defined by WHO stages 3–4. On admission, 4 patients (3%) were taking steroids and 4 (3%) were on insulin treatment.

Forty-one (27%) of 150 patients had stress hyperglycemia as defined by a SHR of more than 1.14. Patients with stress hyperglycemia had significantly higher plasma insulin, HOMA-index, TyG index, and lactate dehydrogenase and lower total and LDL-cholesterol levels than patients without stress hyperglycemia. No significant differences in demographic and anthropometric characteristics, frequency of comorbidities, COVID-19 severity on hospital admission, renal function, and liver tests were observed between patients with or without stress hyperglycemia.

Table 2 reports the levels of cytokines and chemokines that were measured in the study patients. Patients with stress hyperglycemia had significantly higher levels of IL-10, IL-10/TNF-α ratio, CXCL10, and CRP than patients without stress hyperglycemia.

Univariate regression analysis of the relationships of plasma cytokines and chemokines with SHR is shown in Table 3. Analysis showed that IL-10, IL-10/TNF-α ratio, CXCL10, IFN-γ, and CRP were significantly and directly related with SHR values. In multivariate logistic regression models with SHR >1.14 as the dependent variable, log IL-10, IL-10/TNF-α ratio, log CXCL10, and log IFN-γ were separately included together with age, sex, presence of diabetes, CRP, and severity of disease as covariates.
TABLE 1 Clinical characteristics and biochemical variables in patients hospitalized with COVID-19 infection who were grouped according to a Stress Hyperglycemia Ratio (SHR) ≤ 1.14 or > 1.14.

| Variable          | All patients (150) | SHR ≤ 1.14 (109) | SHR > 1.14 (41) | P-value |
|-------------------|--------------------|------------------|-----------------|---------|
| Age (years)       | 69.9 ± 12.4        | 69.9 ± 12.8      | 69.9 ± 13.3     | 0.825   |
| Male sex n (%)    | 53 (35.1)          | 39 (35.7)        | 14 (34.1)       | 0.881   |
| BMI (kg/m²)       | 28.3 ± 5.4         | 28.4 ± 5.8       | 28.1 ± 5.6      | 0.643   |
| Waist Circ. (cm)  | 103.4 ± 13.3       | 103.6 ± 13.4     | 102.6 ± 15.3    | 0.720   |
| WHO 1–2 n (%)     | 57 (38)            | 41 (69)          | 16 (25)         | 0.332   |
| WHO 3–4 n (%)     | 93 (62)            | 33 (67)          | 27 (54)         | 0.268   |
| Hypertension n (%)| 88 (58.6)          | 63 (55.1)        | 23 (60)         | 0.897   |
| Diabetes n (%)    | 56 (37.3)          | 42 (37.2)        | 16 (42)         | 0.925   |
| CV disease n (%)  | 47 (31.3)          | 31 (29)          | 16 (39)         | 0.213   |
| Liver disease n (%)| 13 (8.6)          | 7 (6.1)          | 3 (6)           | 0.495   |
| Malignancy n (%)  | 18 (12)            | 13 (12)          | 5 (12)          | 0.880   |
| Background steroids n (%) | 4 (2.6) | 3 (2) | 1 (4) | 0.767 |
| Statins n (%)     | 35 (23.3)          | 21 (20)          | 14 (34)         | 0.005   |
| Background insulin n (%) | 4 (2.6) | 3 (2.5) | 1 (2.5) | 0.643 |
| Creatinine (mg/dl)| 1.2 ± 1.2          | 1.1 ± 0.7        | 1.4 ± 2         | 0.141   |
| Urea (mg/dl)      | 24.9 ± 12.9        | 24.9 ± 13.7      | 24.8 ± 10       | 0.509   |
| AST (UI/l)        | 42.5 ± 27.6        | 40.7 ± 31        | 44.3 ± 32       | 0.203   |
| ALT (UI/l)        | 42.2 ± 31.6        | 40.1 ± 33.9      | 43.1 ± 27.7     | 0.541   |
| LDH (UI/l)        | 693.7 ± 302        | 659 ± 260        | 783 ± 379       | 0.049   |
| CPK (UI/l)        | 167 (35–169)       | 154 (44–167)     | 202 (133–166)   | 0.417   |
| Uric acid (mg/dl) | 4.8 ± 1.8          | 4.7 ± 2          | 5.3 ± 1.4       | 0.384   |
| Cholesterol (mg/dl)| 150.1 ± 12         | 154 ± 39.5       | 136.2 ± 36.7    | 0.020   |
| HDL-Cholesterol (mg/dl)| 33.4 ± 9.2 | 34.1 ± 9.6 | 32.7 ± 9.7 | 0.792 |
| LDL-Cholesterol (mg/dl)| 87.7 ± 33.5 | 89 ± 33.1 | 74.2 ± 31.9 | 0.036 |
| Triglycerides (mg/dl)| 162.1 ± 58.8 | 160.4 ± 61.8 | 156.9 ± 58.9 | 0.129 |
| Glucose (mmol/l)| 6.5 (5.2–6.4)      | 5.8 (4.8–6.9)    | 10.3 (7.1–12.7) | <0.001 |
| HbA1c (DCCT %)    | 6.5 ± 1.1          | 6.5 ± 1.2        | 6.4 ± 1.1       | 0.328   |
| HbA1C (IFCC mmol/mol)| 48 ± 11          | 48 ± 10          | 46 ± 11         | -       |
| Insulin (nUI/ml)  | 20.9 ± 19.6        | 17.6 ± 14        | 29.9 ± 28       | 0.008   |
| HOMA-IR           | 6.8 ± 7.6          | 4.7 ± 3.9        | 13.1 ± 12.1     | <0.001  |
| TyG Index         | 4.9 ± 0.4          | 4.8 ± 0.26       | 5.1 ± 0.29      | <0.001  |
| SHR               | 0.94 ± 0.35        | 0.8 ± 0.1        | 1.5 ± 0.39      | <0.001  |

WHO, World Health Organization; CV, cardiovascular; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CPK, creatine phosphokinase; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HbA1c, glycated hemoglobin; HOMA-IR, homeostatic model assessment index; TyG, triglyceride/glucose index; SHR, stress hyperglycemia ratio.

As shown in Table 4, log IL-10, IL-10/TNF-α ratio, and log CXCL10, but not log IFN-γ were independently associated with stress hyperglycemia.

At the end of follow-up 32 (21.3%) patients died and 27 (18%) needed invasive mechanical ventilation in ICU. A significantly higher proportion of deaths (36.6% vs. 15.6% \( p < 0.0001 \)) and patients needing invasive mechanical ventilation (34.1% vs. 11.9% \( p < 0.0001 \)) was observed in patients with stress hyperglycemia. In multivariate logistic regression models, we analyzed the association of stress hyperglycemia with use of mechanical ventilation or death occurring within 60 days from hospital admission that were respectively included as the dependent variables (Table 5). Stress hyperglycemia was included in the model as an independent variable alternatively as a SHR value > 1.14 or as SHR tertiles. After correction for age, sex, BMI, presence of diabetes, and severity of COVID-19 stress hyperglycemia was associated with greater use of mechanical ventilation and higher mortality.

**Discussion**

The findings of this study indicate that stress hyperglycemia occurs in more than a quarter of patients who are hospitalized with COVID-19 infection. We observed higher proportion of patients taking Statins in those with Stress Hyperglycemia.
TABLE 2 Plasma levels of cytokines and chemokines in patients hospitalized with COVID-19 infection who were grouped according to a Stress Hyperglycemia Ratio (SHR) ≤ 1.14 or > 1.14.

| Variable     | All patients (150) | SHR ≤ 1.14 (109) | SHR > 1.14 (41) | P-value |
|--------------|--------------------|------------------|-----------------|---------|
| IL-1β (pg/mL) | 0.002 (0.0-0.078)  | 0.001 (0.0-0.097) | 0.001 (0.0-0.014) | 0.245   |
| sIL-2R-α (pg/mL) | 3.899 (2.857-5.449) | 3.895 (2.870-5.197) | 4.002 (2.770-5.653) | 0.546   |
| IL-6 (pg/mL)   | 31.9 (18.5-69.1)   | 35.4 (18.5-84.5)   | 29.5 (20.5-52)   | 0.333   |
| IL-8 (pg/mL)   | 35.6 (24.9-52.6)   | 34.6 (25-52)       | 35.3 (20-55)     | 0.433   |
| IL-10 (pg/mL)  | 15.1 (9-23.1)      | 13.1 (7-19)        | 19.8 (15-27)     | <0.001  |
| IL-10/TNFα ratio | 0.9 (0.5-1.3)     | 0.8 (0.5-1.2)      | 1.2 (0.8-1.6)    | <0.001  |
| CXCL10 (pg/mL) | 1,193 (738-1,778)  | 1,011 (563-1,626)  | 1,515 (1,155-1,972) | <0.001  |
| TNF-α (pg/mL)  | 16.4 (13-21.4)     | 16.1 (13-20)       | 17.9 (13-24)     | 0.819   |
| IFN-γ (pg/mL)  | 1.6 (0.4-3.9)      | 1.3 (0.3-3.4)      | 1.8 (1-4.8)      | 0.637   |
| CRP (mg/dl)    | 89 (36-114)        | 63 (30-100)        | 104 (61-168)     | <0.001  |
| Pro-ADM (pg/mL) | 1.3 ± 0.8         | 1.4 ± 1.2          | 1.15 ± 0.5       | 0.111   |
| Pro-CT (ug/mL) | 0.11 (0.06-0.2)   | 0.1 (0.06-0.2)     | 0.15 (0.1-0.3)   | 0.502   |
| D-Dimere       | 753 (488-1,368)    | 740 (469-1,361)    | 793 (513-1,497)  | 0.478   |

IL-1β, interleukin-1β; IL-6, interleukin-6; IL-8, interleukin-8; TNF-α, tumor necrosis factor-α; CXCL10, C-X-C motif chemokine ligand 10; IFN-γ, interferon-γ; IL-10, interleukin-10; sIL-2R-α, Soluble receptor of interleukin-2; CRP, C-reactive protein; Pro-CT, procalcitonin; Pro-ADM, pro-adrenomedullin.

TABLE 3 Univariate regression analysis of plasma cytokines and chemokines with Stress Hyperglycemia Ratio in patients hospitalized with COVID-19 infection.

| Variables     | R       | P-value |
|---------------|---------|---------|
| IL-1β         | -0.088  | 0.294   |
| sIL-2R-α      | 0.159   | 0.557   |
| IL-6          | -0.104  | 0.211   |
| IL-8          | -0.004  | 0.958   |
| IL-10         | 0.374   | <0.001  |
| IL-10/TNFα ratio | 0.363 | <0.001  |
| CXCL10        | 0.338   | <0.001  |
| TNF-α         | 0.043   | 0.608   |
| IFN-γ         | 0.173   | 0.038   |
| CRP (mg/dl)   | 0.320   | <0.001  |
| Pro-ADM (pg/mL) | 0.119 | 0.166   |

TABLE 4 Multivariate logistic analysis with Stress Hyperglycemia Ratio > 1.14 as the dependent variable.

| Variable     | Standardized coefficient (95% confidence interval) | Odds ratio (95% confidence interval) | P-value |
|--------------|-----------------------------------------------------|--------------------------------------|---------|
| Log IL-10    | 0.352 (0.118-0.587)                                  | 6.74 (1.9-24)                        | 0.003   |
| Log IL-10/TNF-α ratio | 0.331 (0.06-0.58)                                  | 1.53 (1.08-2.11)                     | 0.016   |
| Log CXCL10   | 0.430 (0.162-0.698)                                  | 14.5 (2.5-77)                        | 0.002   |
| Log IFN-γ    | 0.070 (-0.139-0.279)                                 | 1.197 (0.71-2.1)                     | 0.511   |

IL-10, interleukin-10; TNF-α, tumor necrosis factor-α; CXCL10, C-X-C motif chemokine ligand 10; IFN-γ, interferon-γ. Log IL-10, IL-10/TNF-α ratio, log CXCL10, and log IFN-γ were separately included as independent variables together with age, sex, presence of diabetes, C-reactive protein, and severity of disease.

We believe that this difference is due to a slight higher prevalence of patients with Hypertension and CV disease in Stress Hyperglycemia Group (Table 1). Patients with stress hyperglycemia have higher plasma insulin levels and evidence of reduced insulin sensitivity, as suggested by higher HOMA and TyG index, that is independent of preexisting diabetes. In these patients, severity of infection on hospital admission does not differ from patients without stress hyperglycemia, whereas circulating levels of some cytokines that are potentially linked to glucose metabolism are significantly increased. Also, and most important, presence of stress hyperglycemia is an independent predictor of the clinical outcome of COVID-19 patients, both in terms of likelihood of need of mechanical ventilation and death.

Previous studies reported that stress hyperglycemia as assessed by SHR is a better prognostic indicator of clinical outcome than simple blood glucose measurement in patients with stroke (14), sepsis (2), trauma (15) acute myocardial infarction (16), and in patients admitted to general medical wards for acute illness (3). Previous studies have also reported that stress hyperglycemia is associated with poorer outcomes in patients hospitalized with COVID-19 infection (17). Differently, long-term glucose control as assessed by HbA1c levels has no association with the clinical outcome in diabetic patients hospitalized with COVID-19 (18).
TABLE 5 Multivariate logistic models with use of mechanical ventilation (top panel) or death (bottom panel) occurring within 60 day from hospital admission as the dependent variables.

| Mechanical ventilation | SHR > 1.14 | Odds ratio (95% confidence interval) | P value |
|------------------------|------------|-------------------------------------|---------|
| SHR > 1.14             | 2.453 (1.078–6.012) | <0.001                             |
| Tertile I SHR          | reference  |                                     |         |
| Tertile II SHR         | 2.283 (0.833–6.257) | 0.109                              |
| Tertile III SHR        | 6.107 (2.348–15.874) | <0.001                             |

| Death                  | SHR > 1.14 | Odds ratio (95% confidence interval) | P value |
|------------------------|------------|-------------------------------------|---------|
| SHR > 1.14             | 2.781 (1.049–7.369) | <0.001                             |
| Tertile I SHR          | reference  |                                     |         |
| Tertile II SHR         | 3.259 (1.183–8.979) | 0.022                              |
| Tertile III SHR        | 5.149 (1.908–13.891) | <0.001                             |

Stress Hyperglycemia Ratio (SHR) >1.14 or SHR tertiles were separately included as independent variables together with age, sex, presence of diabetes, C-reactive protein, and severity of disease.

support these observations strengthening the view that acute stress hyperglycemia has greater impact on the clinical outcome of COVID-19 patients than chronic glycemic control.

Cytokines and stress hyperglycemia

Because of the high frequency of stress hyperglycemia observed in our COVID-19 patients, we sought to analyze the possible role of several cytokines that could contribute to acute changes of blood glucose levels. In this analysis, levels of IL-10, IL-10/TNF-α ratio, and CXCL10 were found to be independent predictors of stress hyperglycemia as defined by a SHR of more than 1.14. To our knowledge, this is the first study to report independent associations between cytokines and stress hyperglycemia in patients with COVID-19 infection. This observation might have important implications, in particular for CXCL10 that, in addition to pro-inflammatory action (19), could be directly involved in glucose homeostasis. First, it was shown that CLCX10 is released abundantly by the adipose tissue in response to an acute inflammatory response induced by endotoxemia (20), thereby leading to insulin resistance under stress conditions. This might have specific relevance in patients with COVID-19 infection in whom involvement of adipose tissue has a crucial role for the spread of inflammation (21). Second, increased CXCL10 levels are frequently detected in patients with overt type 1 and type 2 diabetes and in subjects at risk of development of diabetes just before its onset (22, 23). In this view, it has been shown that activation of CXCL10 and of its specific receptor CXCR3 could impair pancreatic beta-cell function (23). In animal models of type 1 diabetes, pancreatic insulitis was associated with CXCL10 production and inhibition of the CXCL10/CXCR3 axis prevented development of autoimmune diabetes (24). Moreover, CXCL10 was reported to induce beta-cell apoptosis in type 2 diabetes (25). Along this line, it has been recently demonstrated that extracellular vesicles that are derived from pancreatic beta-cells and are exposed to pro-inflammatory cytokines impair beta-cell activity by activation of the CXCL10/CXCR3 axis (26). Thus, the present study points to an important role of CXCL10 for induction of stress hyperglycemia in COVID-19.

In our patients, stress hyperglycemia was also found to be independently associated with higher levels of IL-10 and by its ratio to TNF-α. IL-10 is a Th2-type cytokine that is produced by a wide range of immunological cell types and has potent anti-inflammatory activity through inhibition of cytokine production (e.g., TNF-α, IL-6) and activity (27). Although the anti-inflammatory action of IL-10 was initially regarded as a beneficial event potentially limiting the damage caused by the systemic inflammatory response, some evidence suggests that an IL-10 excess could be associated with worse clinical outcomes. A role of IL-10 and IL-10/TNF-α ratio as markers of immune paralysis in prediction of adverse outcome was demonstrated in studies conducted in septic patients (28). Moreover, in agreement with our findings, it was reported that patients with stress hyperglycemia during severe sepsis had higher serum levels of IL-10 and worse clinical outcomes when compared to those with normoglycemia or pre-existing diabetes (29).

Other studies suggested that IL-10 might increase insulin sensitivity and blocks the adverse effects of inflammatory cytokines on insulin signaling and glucose homeostasis (30). Therefore, the association observed between IL-10 and stress hyperglycemia might be hypothetically explained as a counter regulatory response to insulin resistance and stress hyperglycemia induced by acute illness (31). Significant positive correlations of IL-10 and other cytokines found in this study would possibly support this hypothesis.

Major strengths of this study are the prospective design and availability of a large database containing clinical, biochemical, and imaging information that permit accurate evaluation of possible relationships of stress hyperglycemia and cytokines with COVID-19 outcomes. There are also some important limitations. First, we included only patients who were hospitalized in a general ward setting and therefore it is not possible to extrapolate findings to other settings of care, such as home or intensive care units. Second, we could evaluate insulin sensitivity only indirectly and we do not have direct markers of insulin secretion. Third we do not have data relative to SARS-CoV2 variant that hits our patients.

Conclusions

The findings of this study demonstrate that stress hyperglycemia is associated with more frequent
need of mechanical ventilation and higher mortality in hospitalized patients with COVID-19 infection independently of diabetes. Results suggest that CXCL10 could have a role in triggering the acute hyperglycemic state in these patients. Further studies will be needed to better understand the complex interactions between cytokines and metabolic dysfunction in COVID-19 patients.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by protocol 14180/O/GEN/ARCS on 19/04/2021. The patients/participants provided their written informed consent to participate in this study.

References

1. Planer D, Witzenbichler B, Guagliumi G, Persugia EJ, Brodie BR, Xu K, et al. Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: the HORIZONS-AMI Trial. J Int J Cardiol. (2015) 167:2572–9. doi: 10.1016/j.ijcard.2012.06.054

2. Fabbri A, Marchesini G, Benazzi B, et al. Stress hyperglycemia and mortality in subjects with diabetes and sepsis. Crit Care Explor. (2020) 2:e0152. doi: 10.1097/CCX.0000000000000152

3. Di Luzio R, Dusi R, Barbanti FA, Calogero P, Marchesini G, Bianchi G. Prognostic value of stress hyperglycemia in patients admitted to medical/geriatric departments for acute medical illness. Diabetes Ther. (2021) 2:1–15. doi: 10.1007/s13300-021-01183-y

4. Gunst J, De Bruyn A, Van den Bergh G. Glucose control in the ICU. Curr Opin Anaesthesiol. (2019) 32:156–62. doi: 10.1097/ACO.0000000000000706

5. Satish T, Kapoor N, Cao Y, Tapp RJ, Zimmet P. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes Metab. (2021) 23:870–4. doi: 10.1111/dom.14269

6. Li H, Tian S, Chen T, Cui Z, Shi N, Zhong X, et al. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 in hospitalized patients with COVID-19. Diabetes Obes Metab. (2020) 22:1897–906. doi: 10.1111/dom.14099

7. Alhumaid S, Al Mutair A, Al Alawi Z, et al. Diabetic ketoacidosis in patients with SARS-CoV-2: a systematic review and meta-analysis. Diabetol Metab Syndr. (2021) 13:120. doi: 10.1186/s13498-021-00740-6

8. Armeni E, Aziz U, Qamar S, Nasir S, Negus R, et al. Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series. Lancet Diabetes Endocrinol. (2020) 8:660–3. doi: 10.1016/S2213-8587(20)30221-7

9. McGowan KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin. (2001) 17:107–24. doi: 10.1016/S0704-8740(03)70154-8

10. Kajbaf F, Mojtahzedazdeh M, Abdollahi M. Mechanisms underlying stress-induced hyperglycemia in critically ill patients. Therapy. (2007) 4:97–106. doi: 10.21317/tj0798.4.1.97

11. Accili D. Can COVID-19 cause diabetes? Nat Metab. (2021) 3:123–5. doi: 10.1038/s42255-020-00339-7

12. Donath MY, Sterling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med. (2003) 81:455–70. doi: 10.1007/s00109-003-0450-y

13. Roberts GW, Quinn SJ, Valentine N, Alhawasst I, O’Dea H, Stranks SN, et al. Relative hyperglycemia, a marker of critical illness: introducing the stress hyperglycemia ratio. J Clin Endocrinol Metab. (2015) 100:4490–7. doi: 10.1210/jc.2015-2660

14. Roberts G, Sires J, Chen A, Thynne T, Sullivan C, Quinn S, et al. Comparison of the stress hyperglycemia ratio, glycemic gap, and glucose to assess the impact of stress-induced hyperglycemia on ischemic stroke outcome. J Diabetes. (2021) 13:1034–42. doi: 10.1111/1753-0407.13232

15. di Luzio R, Dusi R, Mazzotti A, Petroni M, Marchesini G, Bianchi G. Stress hyperglycaemia and complications following traumatic injuries in individuals with/without diabetes: the case of orthopedic surgery. Diabetes Metab Syndr Obes. (2020) 13:9–17. doi: 10.2147/DMSO.S235796

16. Chen G, Li M, Wen X, Wang R, Zhou Y, Xue L, et al. Association between stress hyperglycemia ratio and in-hospital outcomes in elderly patients with acute myocardial infarction. Front Cardiovasc Med. (2021) 8:698725. doi: 10.3389/fcmv.2021.698725

17. Fadini GP, Morri DI, Boscari F, Fioretto P, Maran A, Buettner L, et al. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res Clin Pract. (2020) 168:108374. doi: 10.1016/j.diabres.2020.108374

18. Carriu R, Hadjad SJ, Warny M, Pichelin M, Al-Salemeh A, Allix I, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. (2020) 63:1500–15. doi: 10.1007/s00125-020-05180-x

19. Coperchini F, Chiavotto L, Rotondi M. Interleukin-6, CXCL10 and infiltrating macrophages in COVID-19-Related cytokine storm: not one for all but all for one! Front Immunol. (2021) 12:668507. doi: 10.3389/fimmu.2021.668507

Author contributions

AD and MP: design study. MF, CP, and FC: laboratory analysis. MA, LB, EG, and CD: practical performance. GC and AD: data analysis. AD and LS: preparation of manuscript. CT, ES, and CC: critical review. All authors have read and agreed to the published version of the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
20. Mehta NN, McGillicuddy FC, Anderson PD, Hinkle CC, Shah R, Pruscino L, et al. Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes. (2010) 59:172–81. doi: 10.2337/db09-0367

21. Steenblock C, Schwarz PEH, Ludwig B, Linkermann A, Zimmet P, Kulebyakin K, et al. COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol. (2021) 9:786–798. doi: 10.1016/S2213-8587(21)00244-8

22. Shigihara T, Oikawa Y, Kanazawa Y, Okubo Y, Narumi S, Saruta T, Shimada A. Significance of serum CXCL10/IP-10 level in type 1 diabetes. J Autoimmun. (2006) 26:66–71. doi: 10.1016/j.jaut.2005.09.027

23. Paroni F, Domnegen E, Maedler K. CXCL10- a path to β-cell death. Islets. (2009) 1:256–9. doi: 10.4161/isl.1.3.9110

24. Morimoto J, Yoneyama H, Shimada A, Shigihara T, Yamada S, Oikawa Y, et al. CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis. J Immunol. (2004) 173:7017e2. doi: 10.4049/jimmunol.173.11.7017

25. Herder C, Baumert J, Thorand B, Koenig W, De Jager W, Meisinger C, et al. Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984–2002. Diabetologia. (2006) 49:921. doi: 10.1007/s00125-006-0190-y

26. Javeed N, Her TK, Brown MR, Vanderboom P, Rakshit K, Egan AM, et al. Pro-inflammatory β cell small extracellular vesicles induce β cell failure through activation of the CXCL10/CXCR3 axis in diabetes. Cell Rep. (2021) 36:109613. doi: 10.1016/j.celrep.2021.109613

27. Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. (2010) 10:170–81. doi: 10.1038/nri2711

28. Hamers L, Kox M, Pickkers P. Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options. Minerva Anestesiol. (2015) 81:426–39.

29. Leonidou L, Mouzaki A, Michalaki M, DeLastic AL, Kyriazopoulou V, Bassaris HP, et al. Cytokine production and hospital mortality in patients with sepsis-induced stress hyperglycemia. J Infect. (2007) 55:340–6. doi: 10.1016/j.jinf.2007.05.177

30. Hong EG, Ko HJ, Cho YR, Kim HJ, Ma Z, Yu TY, et al. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes. (2009) 58:2525–35. doi: 10.2337/db08-1261

31. Dagdeviren S, Jung DY, Lee E, Friedline RH, Noh HI, Kim JH, et al. Altered Interleukin-10 Signaling in Skeletal Muscle Regulates Obesity-Mediated Inflammation and Insulin Resistance. Mol Cell Biol. (2016) 36:2956–66. doi: 10.1128/MCB.00181-16